gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1746Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL ARTICLESЭффективность применения альгинатов в лечении изжоги у беременныхEfficacy of application of alginates in treatment of a heartburn at pregnant womenОнучинаЕ. В.OnuchinaE. V.ГоробецЭ. А.GorobetsE. A.РожанскийА. А.RozhanskyA. A.ЦукановВ. В.TsukanovV. V.2009181220091962327Copyright © Онучина Е.В., Горобец Э.А., Рожанский А.А., Цуканов В.В., 20092009Онучина Е.В., Горобец Э.А., Рожанский А.А., Цуканов В.В.Onuchina E.V., Gorobets E.A., Rozhansky A.A., Tsukanov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1746

Цель исследования. Оценить частоту, факторы возникновения изжоги у беременных, определить тактику медикаментозного лечения альгинатами.Материал и методы. У 110 беременных женщин с помощью шкалы Ликерта оценивали частоту и выраженность изжоги, проводили антропометрию и при наличии изжоги эзофагогастродуоденоскопию.Результаты. Общая частота симптома изжоги в исследуемой группе составила 56,4%. Еженедельная изжога выявлена у каждой второй беременной (49,1%). Наибольшее влияние на ее развитие оказали: наличие изжоги до беременности, избыточная масса тела или ожирение до и во время беременности, наличие родственников, страдающих изжогой, наличие изжоги в предыдущую беременность, курение до беременности. Частота и выраженность изжоги без медикаментозной коррекции нарастали по мере увеличения сроков беременности. На фоне приема Гевискона форте в дозе 10 мл/сут в режиме по требованию к 4-­й неделе исследования наблюдали достоверное снижение общей частоты и выраженности изжоги, полное купирование еженедельной, ежедневной и ночной изжоги.Выводы. Изжога служит частым симптомом при беременности, для ее лечения может быть успешно использован препарат альгиновой кислоты.

Aim of investigation

Aim of investigation. To estimate frequency, factors of development of heartburn at pregnant women, to determine approach of pharmaceutical treatment by alginates.

Material and methods

Material and methods. At 110 pregnant women frequency and severity of heartburn were estimated by Likert scale, anthropometry and esophagogastroduodenoscopy at presence of heartburn were carried out.

Results

Results. General frequency of symptom of heartburn in studied group was 56,4%. The weekly heartburn was revealed at every other pregnant woman (49,1%). The greatest effect on its development had: presence of heartburn prior pregnancy, excessive body weight or obesity before and during pregnancy, presence of the relatives having heartburn, presence of heartburn during previous pregnancy, smoking before pregnancy. Frequency and severity of heartburn without pharmacological correction grew along with gestation term. On a background of Gaviscon forte treatment 10 ml/day in on-demand mode by the 4-th week of the study significant decrease of total frequency and severity of heartburn, complete relief of weekly, daily and night heartburn was observed.

Conclusion

Conclusion. The heartburn is a frequent symptom at pregnancy, alginic acid drug can be successfully utilised for its treatment.

симптом изжогибеременностьальгинатыГевискон фортеsymptom of heartburnpregnancyalginatesGaviscon-forteReferencesAnton C., Anton E., Drug V.L., Stanciu C. Hormonal influence on gastrointestinal reflux during pregnancy // Rev. Med. Chir. Soc. Med. Nat. Iasi. – 2003. – Vol. 107. – P. 798–801.Anton C., Anton E., Drug V.L., Stanciu C. Hormonal influence on gastrointestinal reflux during pregnancy // Rev. Med. Chir. Soc. Med. Nat. Iasi. – 2003. – Vol. 107. – P. 798–801.Bor S., Kitapcioglu G., Dettmar P., Baxter T. Associa­tion of heartburn pregnancy with the risk of gastroesophageal reflux disease // Clin. Gastroenterol. Hepatol. – 2007. – Vol. 5. – P. 1035–1039.Bor S., Kitapcioglu G., Dettmar P., Baxter T. Associa­tion of heartburn pregnancy with the risk of gastroesophageal reflux disease // Clin. Gastroenterol. Hepatol. – 2007. – Vol. 5. – P. 1035–1039.Dowswell T., Neilson J.P. Interventions for heartburn in pregnancy // Cochrane Database Syst. Rev. – 2008. Oct. 8; (4):CD007065.Dowswell T., Neilson J.P. Interventions for heartburn in pregnancy // Cochrane Database Syst. Rev. – 2008. Oct. 8; (4):CD007065.Eslick G.D., Talley N.J. Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study // J. Clin. Gastroenterol. – 2009. – Vol. 43. – P. 111–117.Eslick G.D., Talley N.J. Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study // J. Clin. Gastroenterol. – 2009. – Vol. 43. – P. 111–117.Fil S., Malfertheiner M., Costa S.D., Monkemuller K. Handling of the gastroesophageal reflux disease (GERD) during pregnancy-a review // Z. Geburtshilfe Neonatol. – 2007. – Vol. 211. – P. 215–223.Fil S., Malfertheiner M., Costa S.D., Monkemuller K. Handling of the gastroesophageal reflux disease (GERD) during pregnancy-a review // Z. Geburtshilfe Neonatol. – 2007. – Vol. 211. – P. 215–223.Gill S.K., OўBrien L., Einarson T.R., Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis // Am. J. Gastroenterol. – 2009. – Vol. 104. – P. 1541–1545.Gill S.K., OўBrien L., Einarson T.R., Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis // Am. J. Gastroenterol. – 2009. – Vol. 104. – P. 1541–1545.Hatlebakk J.G. Treatment of gastroesophageal reflux in pregnant women // Tidsskr. Nor. Laegeforen. – 2004. – Vol. 124. – P. 797–798.Hatlebakk J.G. Treatment of gastroesophageal reflux in pregnant women // Tidsskr. Nor. Laegeforen. – 2004. – Vol. 124. – P. 797–798.Keller J., Frederking D., Layer P. The spectrum and treatment of gastrointestinal disorders during pregnancy // Nat. Clin. Pract. Gastroenterol. Hepatol. – 2008. – Vol. 5. – P. 430–433.Keller J., Frederking D., Layer P. The spectrum and treatment of gastrointestinal disorders during pregnancy // Nat. Clin. Pract. Gastroenterol. Hepatol. – 2008. – Vol. 5. – P. 430–433.Lindow S.W., Regnell P., Sykes J., Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy // Int. J. Clin. Pract. – 2003. – Vol. 3. – P. 175–179.Lindow S.W., Regnell P., Sykes J., Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy // Int. J. Clin. Pract. – 2003. – Vol. 3. – P. 175–179.Mahadevan U., Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy // Gastroenterology. – 2006. – Vol. 131. – P. 278–282.Mahadevan U., Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy // Gastroenterology. – 2006. – Vol. 131. – P. 278–282.Mandel K.G., Daggy B.P., Brodie D.A., Jacoby H.I. Review article: alginate-raft formulation in the treatment of heartburn and acid reflux // Aliment. Pharmacol. Ther. – 2000. – Vol. 14. – P. 669–690.Mandel K.G., Daggy B.P., Brodie D.A., Jacoby H.I. Review article: alginate-raft formulation in the treatment of heartburn and acid reflux // Aliment. Pharmacol. Ther. – 2000. – Vol. 14. – P. 669–690.Marrero J.M., Goggin P.M., de Caestecker J.S. et al. Determinants of pregnancy heartburn // Br. J. Obstet. Gynaecol. – 1992. – Vol. 99. – P. 731–734.Marrero J.M., Goggin P.M., de Caestecker J.S. et al. Determinants of pregnancy heartburn // Br. J. Obstet. Gynaecol. – 1992. – Vol. 99. – P. 731–734.Nocon M., Labenz J., Jaspersen D. et al. Association of body mass index with heartburn, regurgitation and esophagitis: results of the progression of gastroesophageal reflux disease study // J. Gastroenterol. Hepatol. – 2007. – Vol. 22. – P. 1728–1731.Nocon M., Labenz J., Jaspersen D. et al. Association of body mass index with heartburn, regurgitation and esophagitis: results of the progression of gastroesophageal reflux disease study // J. Gastroenterol. Hepatol. – 2007. – Vol. 22. – P. 1728–1731.Rey E., Rodriguez-Artalejo F., Herraiz M.A. et al. Gastroesophageal reflux symptoms duiring and after pregnancy: a longitudinal study // Am. J. Gastroenterol. – 2007. – Vol. 102. – P. 2395–2400.Rey E., Rodriguez-Artalejo F., Herraiz M.A. et al. Gastroesophageal reflux symptoms duiring and after pregnancy: a longitudinal study // Am. J. Gastroenterol. – 2007. – Vol. 102. – P. 2395–2400.Richter J.E. Review article: the management of heartburn in pregnancy // Aliment. Pharmacol. Ther. – 2005. – Vol. 22. – P. 749–757.Richter J.E. Review article: the management of heartburn in pregnancy // Aliment. Pharmacol. Ther. – 2005. – Vol. 22. – P. 749–757.Tytgat G.N., Heading R.C., Muller-Lissner S. et al. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meetin // Aliment. Pharmacol. Ther. – 2003. – Vol. 18. – P. 291–301.Tytgat G.N., Heading R.C., Muller-Lissner S. et al. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meetin // Aliment. Pharmacol. Ther. – 2003. – Vol. 18. – P. 291–301.Vakil N., van Zanten S., Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus // Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 1900–1920.Vakil N., van Zanten S., Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus // Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 1900–1920.

The authors declare that there are no conflicts of interest present.